Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

The U.S. Food and Drug Administration (FDA) has approved several label updates for CAR-T cell therapies marketed by Bristol ...

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

Pharmaceutical company Novartis and the organization working to increase representation in advertising, the Cannes Can: ...

Novartis AG offers growth potential with a balanced drug portfolio, manageable debt, and shares priced below fair value.

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was ...

Enhanced treatment options, precision medicine, and advanced diagnostics are fueling growth across major markets Zollinger ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

After its $1 billion acquisition by Novartis, Mariana Oncology is expanding its Massachusetts real estate. Biotech's Future - ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...